5KVD image
Deposition Date 2016-07-14
Release Date 2016-08-03
Last Version Date 2024-10-23
Entry Detail
PDB ID:
5KVD
Title:
Zika specific antibody, ZV-2, bound to ZIKA envelope DIII
Biological Source:
Source Organism:
Zika virus (Taxon ID: 64320)
Mus musculus (Taxon ID: 10090)
Host Organism:
Method Details:
Experimental Method:
Resolution:
1.65 Å
R-Value Free:
0.22
R-Value Work:
0.19
R-Value Observed:
0.19
Space Group:
P 21 21 21
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Zika Envelope DIII
Chain IDs:A (auth: E)
Chain Length:110
Number of Molecules:1
Biological Source:Zika virus
Polymer Type:polypeptide(L)
Molecule:ZV-2 Antibody Fab Heavy Chain
Chain IDs:C (auth: H)
Chain Length:222
Number of Molecules:1
Biological Source:Mus musculus
Polymer Type:polypeptide(L)
Molecule:ZV-2 Antibody Fab Light Chain
Chain IDs:B (auth: L)
Chain Length:220
Number of Molecules:1
Biological Source:Mus musculus
Primary Citation
Structural Basis of Zika Virus-Specific Antibody Protection.
Cell 166 1016 1027 (2016)
PMID: 27475895 DOI: 10.1016/j.cell.2016.07.020

Abstact

Zika virus (ZIKV) infection during pregnancy has emerged as a global public health problem because of its ability to cause severe congenital disease. Here, we developed six mouse monoclonal antibodies (mAbs) against ZIKV including four (ZV-48, ZV-54, ZV-64, and ZV-67) that were ZIKV specific and neutralized infection of African, Asian, and American strains to varying degrees. X-ray crystallographic and competition binding analyses of Fab fragments and scFvs defined three spatially distinct epitopes in DIII of the envelope protein corresponding to the lateral ridge (ZV-54 and ZV-67), C-C' loop (ZV-48 and ZV-64), and ABDE sheet (ZV-2) regions. In vivo passive transfer studies revealed protective activity of DIII-lateral ridge specific neutralizing mAbs in a mouse model of ZIKV infection. Our results suggest that DIII is targeted by multiple type-specific antibodies with distinct neutralizing activity, which provides a path for developing prophylactic antibodies for use in pregnancy or designing epitope-specific vaccines against ZIKV.

Legend

Protein

Chemical

Disease

Primary Citation of related structures